:::

詳目顯示

回上一頁
題名:某醫學中心抗結核藥物之藥物不良反應案例分析
書刊名:臺灣臨床藥學雜誌
作者:楊紫麟陳啟佑黃耀斌廖芬芬
作者(外文):Yang, Tzu-linChen, Chi-yuHuang, Yaw-binLiao, Fen-fen
出版日期:2011
卷期:19:2
頁次:頁75-88
主題關鍵詞:抗結核藥物藥物不良反應Antituberculous agentsAdverse drug reactionsNaranjo algorithm
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:0
  • 共同引用共同引用:1
  • 點閱點閱:11
期刊論文
1.林國華、遲蘭慧、顏秀瓊(2008)。九十六年度藥害救濟審議案例分析。藥物安全簡訊,21,20-28。  延伸查詢new window
2.遲蘭慧、林國華、顏秀瓊(2009)。九十七年度藥害救濟審議案例分析。藥物安全簡訊,25,17-28。  延伸查詢new window
3.林國華、呂雅雯、顏秀瓊(2010)。九十八年度藥害救濟審議案例分析。藥物安全簡訊,29,17-28。  延伸查詢new window
4.廖芬芬、陳啟佑、黃耀斌、楊紫麟(20081200)。某醫學中心藥品不良反應的案例分析。臺灣臨床藥學雜誌,16(4),65-74。new window  延伸查詢new window
5.Martin, R. M.、Biswas, P. N.、Freemantle, S. N.、Pearce, G. L.、Mann, R. D.(1998)。Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies。Br J Clin Pharmacol,46,505-511。  new window
6.McLean, A. J.、Le Couteur, D. G.(2004)。Aging biology and geriatric clinical pharmacology。Pharmacol Rev,56,163-184。  new window
7.陳映蓉、陳燕惠(2005)。抗結核藥物之藥物不良反應通報現況。藥物安全簡訊,10,19-28。  延伸查詢new window
8.Aquinas, M.、Allan, W. Q.、Horsfall, P. A.、Jenkins, P. K.、Hung-Yan, W.、Girling, D.(1972)。Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong。Br Med J,1,765-771。  new window
9.Perdu, D.、Lavaud, F.、Prevost, A.、Deschamps, F.、Cambie, M. P.、Bongrain, E.(1996)。Erythema multiforme due to pyrazinamide。Allergy,51,340-342。  new window
10.Fritsch, P. O.、Sidorof, F. A.(2000)。Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis。Am J Clin Dermatol,1,349-360。  new window
11.Letko, E.、Papaliodis, D. N.、Papaliodis, G. N.、Daoud, Y. J.、Ahmed, A. R.、Foster, C. S.(2005)。Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature。Ann Allergy Asthma Immunol,94,419-438+456。  new window
12.Thompson, N. P.、Caplin, M. E.、Hamilton, M. I.、Gillespie, S. H.、Clarke, S. W.、Burroughs, A. K.(1995)。Anti-tuberculosis medication and the liver: dangers and recommendations in management。Eur Respir J,8,1384-1388。  new window
13.Steele, M. A.、Burk, R. F.、DesPrez, R. M.(1991)。Toxic hipatitis with isoniazid and rifampin: a meta-analysis。Chest,99,456-471。  new window
14.Durand, F.、Bemuau, J.、Pessayre, D.、Samuel, D.、Belaiche, J.、Degott, C.(1995)。Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid。Hepatology,21,929-932。  new window
15.Johnson, D. H.、Cunha, B. A.(1996)。Drug fever。Infect Dis Clin North Am,10,85-91。  new window
16.Patel, R. A.、Gallagher, J. C.(2010)。Drug fever。Pharmacotherapy,30,57-69。  new window
17.Martinez, E.、Collazos, J.、Mayo, J.(1999)。Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions。Medicine,78,361-9。  new window
18.Scott, J. T.(1991)。Drug-induced gout。Baillieres Clin Rheumatol,5,39-60。  new window
19.Postlethwaite, A. E.、Bartel, A. G.、Kelley, W. N.(1974)。Hyperuricemia induced by ethambutol。Adv Exp Med Biol,41,763-767。  new window
20.Wenning, G. K.、O'Connell, M. T.、Patsalos, P. N.、Quinn, N. P.(1995)。A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease。Mov Disord,10,664-667。  new window
21.Gershanik, O. S.、Luquin, M. R.、Scipioni, O.、Obeso, J. A.(1988)。Isoniazid therapy in Parkinson's disease。Mov Disord,3,133-139。  new window
22.Park, J. Y.、Kim, K. A.、Park, P. W.、Park, C. W.、Shin, J. G.(2003)。Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide。Clin Pharmacol Ther,74,334-340。  new window
23.Durand, F.、Jebrak, G.、Pessayre, D.、Fournier, M.、Bernuau, J.(1996)。Hepatotoxicity of antitubercular treatments: rationale for monitoring liver status。Drug Safety,15(6),394-405。  new window
24.Naranjo, C. A.、Busto, U.、Sellers, E. M.、Sandor, P.、Ruiz, I.、Roberts, E. A.、Janecek, E.、Domecq, C.、Greenblatt, D. J.(1981)。A method for estimating the probability of adverse drug reactions。Clinical Pharmacology & Therapeutics,30(2),239-245。  new window
學位論文
1.張秀娟(2006)。個案管理模式於肺結核病患照護之成效(碩士論文)。慈濟大學。  延伸查詢new window
圖書
1.行政院衛生署疾病管制局(2008)。結核病診治指引。行政院衛生署疾病管制局。  延伸查詢new window
其他
1.(1498)。疾病介紹:結核病,http://www.cdc.gov.tw/sp.asp7xdurHdisease /disease_content.asp&id=777&mp=l&ctnod e=1498#l。  new window
2.Micromedex® Healthcare Series,Greenwood Village, Colorado, USA。,http://www.thomsonhc.com., 2009/05/25。  new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
QR Code
QRCODE